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GenBank Accession number, D17629
N-acetylgalactosamine-6-sulfate sulfatase E.C.
number 3.1.6.4
Mucopolysaccharidosis IVA (MPS IVA, Mor-
quio type A) OMIM disorder/gene accession
number, 253000tudies of mutated mRNAs have not been carried out on Morquio A patients. Such
studies are very important for the determination of stability of premature termination codons (PTC) bearing
transcripts in order to assess the appropriateness of introducing the newly developed therapeutic strategies
such as “stop codon read-through therapy”.
Methods: This paper focuses on the study of the GALNS gene and mRNAs in two severe forms of Morquio A
patients' fibroblasts with development of a new and rapid real-time RT-PCR for detection and quantification
of absolute mRNA copy number.
Results:We identified two newmutations c.385ANT (p.K129X) and c.899−1GNC) in Pt1 and a known splicing
defect c.120+1GNA in Pt2. Using RT-PCR and real-time RT-PCR in Pt2 we detected low levels of mRNAs,
suggesting its instability; in Pt1, we detected three aberrant mRNAs introducing premature stop codons,
suggesting that both the c.385ANT and c.899−1GNC mutations produce mRNAs capable of escaping the
nonsense-mediated decay (NMD) pathway.
Conclusions: The development of a real-time RT-PCR assay allows to absolutely quantify the GALNS mRNAs
carrying mutations that lead to PTCs bearing transcripts, which escape the NMD process and are potentially
suitable for the new therapeutic approach.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Deficiency of the lysosomal enzyme N-acetylgalactosamine-6-
sulfate sulfatase (GALNS; E.C. 3.1.6.4; OMIM 253000) leads to mucopo-
lysaccharidosis IVA (MPS IVA: Morquio type A). GALNS hydrolyses the
sulfate ester groups of galactose-6-sulfate at the nonreducing end of
keratan sulphate (KS) and of N-acetylgalactosamine-6-sulfate (Gal-
NAc6S) at the nonreducing end of condroitin-6-sulfate (C6S) [1,2].
MPS IVA patients show a broad spectrum of clinical severity,
ranging from classical (severe) forms to milder phenotypes. Classical
forms are characterised by a lifespan of 20–30 years, short trunk
dwarfism, spondyloepiphyseal dysplasia, coxa valga, odontoid hypo-ate sulfatase; MPS IVA, muco-
ne-6-sulfate; KS, keratan sul-
ain reaction; RT-PCR, reverse
ure termination codon; NMD,
se.
9 55 570380.
ll rights reserved.plasia, corneal clouding, preservation of intelligence, hepatospleno-
megaly and an excessive urinary excretion of KS and C6S [3,4]. Mild
forms imply little bone and visceral organ involvement and a
relatively good quality of life until 50–60 years of age [5,6].
The GALNS enzyme is encoded by the GALNS gene, the latter,
mapped on chromosome 16q24.3 [7–9], encompassing about 50 kb
and organized in 14 exons and 13 introns [10].
About 150 mutations have so far been identified, revealing a high
degree of genetic heterogeneity that is probably responsible for the
clinical variability in MPS IVA patients.
Only a few studies have been carried out on human GALNS mRNA
[10,11] none ofwhich includingmRNAquantification by real-time PCR.
However mRNAs quantification can be helpful in studying mutations
causing disease such as splicing and nonsense alterations. These
mutations can cause very unstable mRNA transcripts or transcripts
capable of escaping the nonsense-mediated decay (NMD) pathway, a
molecular mechanism that reduces the amount of transcripts carrying
premature termination codons (PTCs). Consequently toxic or gain-of-
function proteins would be generated [12], resulting in different
phenotypes. Here we report characterisation of GALNS genemutations
Table 2






galns 1F Sense −168/−148 ntb 5′ CTGGTCACGAGGCAGTCCAG3 ′ 351
galns 1R Antisense +46/+64 nt 5′ CTCCATCCGCCCCTCCCCT 3′
Exon 2
galns 2F Sense −54/−34 nt 5′ CCAGAAGCACCTGCAGAAGGC 3′ 231
galns 2R Antisense +34/+53 nt 5′ CCTCGGCCTGTTGGGCTCAC 3′
Exon 3
galns 3F Sense −65/−46 nt 5′ GTTGACGCCCGGGGTCTGAG 3′ 208
galns 3R Antisense +49/+68 nt 5′ CACCACCCGTAGCCCACCTG 3′
Exon 4
galns 4F Sense −66/−46 nt 5′ GTTAGGATGGGGTTGGTGGCA 3′ 231
galns 4R Antisense +42/+62 nt 5′ GGAACCAAGGCCAGGAAGTGG 3′
Exon 5
galns 5F Sense −51/−33 nt 5′ CCGAGTGTCCCCACGTGGG 3′ 245
galns 5R Antisense +31/+50 nt 5′ CGGGCACAGCAGTTCAGGAC 3′
Exon 6
galns 6F Sense −71/−51 nt 5′ GGTGAAATCAGGGAGAACGGG 3′ 205
galns 6R Antisense +48/+67 nt 5′ GGATGAGGTTGGTGCGGTCC 3′
Exon 7
galns 7F Sense −67/−49 nt 5′ GGGGACCGTGGGAGGCATG 3′ 279
galns 7R Antisense +48/+68 nt 5′ CCCATCTCTGGAGTCAAGCAC 3′
Exon 8
galns 8F Sense −70/−51 nt 5′ GCCGTTGGCTGCCTGATCCA 3′ 277
galns 8R Antisense +48/+67 nt 5′ GGTCCAGGCACTCTTCGCTG 3′
Exon 9
galns 9F Sense −107/−88 nt 5′ CCGGGCCCTTTGTCCCTATG 3′ 284
galns 9R Antisense +55/+73 nt 5′ GAGGGGCGCACACACCCTG 3′
Exon 10
galns 10F Sense −72/−54 nt 5′ CCCAGGGATTGGCCCCCAG 3′ 292
galns 10R Antisense +65/+83 nt 5′ GGCCTGGGGGTTGCACCTG 3′
Exon 11
galns 11F Sense −69/−51 nt 5′ CCCAGAGCCTCCAGGTGGC 3′ 239
galns 11R Antisense +49/+67 nt 5′ GCTCAGGGGCCACGTCTGG 3′
Exon 12
galns 12F Sense −120/−101 nt 5′ CTCTGTCCCTGTGGAGCCTG 3′ 321
galns 12R Antisense +60/+79 nt 5′ CTCTGTCCCTGTGGAGCCTG 3′
Exon 13
galns 13F Sense −69/−51 nt 5′ GTCCAGGCCAGCCCCTCTC 3′ 261
galns 13R Antisense +56/+74 nt 5′ CGGTTCATCCTGGGCCCCG 3′
Exon 14
galns 14F Sense −67/−49 nt 5′ CCGCTGCTGCTGGGTCCAG 3′ 533
73L. Carraresi et al. / Clinica Chimica Acta 397 (2008) 72–76andmRNA stability verifying a genotype/phenotype correlation in two
MPS IVA patients with a severe form.
2. Materials and methods
2.1. Patients
The clinical and biochemical findings of the two patients (Pt1 and Pt2) are shown in
Table 1. Deficiency of GALNS enzyme activity was confirmed on fibroblasts by the
fluorogenic method previously reported by Van Diggelen et al. [13].
The molecular study was performed after informed consent, for genetic testing
from patients' parents, was obtained.
2.2. Analysis of genomic DNA
To identify genetic lesions in the GALNS gene, genomic DNA was isolated from
peripheral blood lymphocytes and fibroblasts. The GALNS exons were amplified with
the primers reported in Table 2.
Amplification of genomic fragments was performed on 400 ng of genomic DNA and
PCR conditions for all the exons were: denaturation at 94 °C for 5 min, 28 cycles at 94 °C
for 1 min, 65 °C for 1 min, 72 °C for 1 min, and a final extension cycle at 72 °C for 10 min.
PCR products were visualized on a 2% agarose gel, excised and purified using
Nucleospin Extract II extraction kit (MACHEREY-NAGEL, Duren, Germany). About
100 ng of purified DNA was analyzed for mutation detection by nucleotide sequencing
on ABI PRISM 310 Genetic Analyzer using BigDye terminator chemicals (Applied
Biosystems, Foster City, CA).
2.3. RNA isolation and retrotranscription
Isolation of total RNA from cultured skin fibroblasts was performed with the TRIzol
reagent (Life Technologies, Rockville, MD). RNA integrity and concentrations were both
checked by 1% agarose gel and Nanodrop® ND-1000 Spectrophotometer (Nanodrop
technologies, Wilmington, USA).
RNA reverse transcription was carried out as follows:
1. 1–7 μg of total RNAs were reverse transcribed with Display THERMO-RT (Eppendorf,
Hamburg, Germany) using the specific 3′ UTR primer 5′ GGAGGGTCCTGAAA-
TCTGAGG 3′, according to the manufacturer.
2. 400 ng total RNAs were reverse transcribed in 80 μl of final volume in a reaction
mixture containing 10 μl TaqMan RT buffer 1×, 5.5 mM MgCl2, 500 μM each dNTP,
2.5 μM random hexamers, 0.4 U/μl RNase Inhibitor and 1.25 U/μl Multi-
Scribe Reverse transcriptase provided by Applied Biosystems. The profile of the
one-step reverse transcriptase was: 10 min at 25 °C, 30 min at 48 °C and 2 min at
95 °C.
The reverse transcripts obtained from the second method were used for
quantitative real-time analysis.Table 1
Clinical, biochemical and molecular data of MPS IV A patients
Patient 1 Patient 2
Sex F F
Age at diagnosis (y) 1 2












Parents' consanguinity No Yes
At present Age (y) 9 7
Height(cm) 91 89




Chest deformity Yes Yes
Hearing loss Yes Yes
Corneal clouding Yes Yes
Coxa valga Yes Yes

















a Numbered from each intron/exon junction according to den Dunnen et al. [14,15].
b 1 is the adenine of the initiator Met.
c 1 is the guanine of the stop codon.2.4. RT-PCR analysis
A first full length reverse transcriptase PCR (RT-PCR) was performed with the
following amplification primers:I° PCR Primer forward GALNS c1F 5′ CAGCCCAGCCGGAAGGGCC 3′ or
GALNS OMF139 5′ CGGGGCTCCGCGGCTCCCGTGGTTG 3′
Primer reverse GALNS c6R 5′ GGCAAAGCTGAGGGGGAACC 3′1–3 μl of first RT-PCR amplification was used as a template in a nested PCR using the
following primers:II° PCR (nested) Primer forward GALNS c1F 5′ CAGCCCAGCCGGAAGGGCC 3′ or
GALNS c2F 5′ GGACCGGATGGCTGCAGAA 3′ or
GALNS c3F 5′ CAAGGCCAGGCCCAACATCC 3′
Primer reverse GALNS c3R 5′ CGCCGTTGTCCGACGTGAAG 3′ or
GALNS c5R 5′ ACACGTTGAGCTGGGGCTGC 3′Cycle conditions were the same as those used for the analysis of genomic DNA.
2.5. Mutation nomenclature
The reported mutations are described according to mutation nomenclature (http://
www.hgvs.org/mutnomen/recs.html) considering nucleotide +1 the A of the first ATG
74 L. Carraresi et al. / Clinica Chimica Acta 397 (2008) 72–76translation initiation codon [14,15]. Nucleotide numbers are derived from cDNA GALNS
sequence (EMBL/Gen Bank/ DDBJ; accession number NM_000512).
2.6. Quantification of GALNS mRNA
The measurement of GALNS gene mRNA was performed using a quantitative real-
time RT-PCR method, based on TaqMan™ technology. Probe and primers were selected
by the computer program “Primer Express” (Applied Biosystems, Foster City, USA). For
the detection of GALNS mRNA the following probe and primers were chosen on GALNS
cDNA (1569 bp): probe 635/649 nt: 5′ AAGCCCTGGACTTCA 3′ labeled with FAM, located
on exon 7, forward primer 608/629 nt: 5′ CCAACCTCACCCAGATCTACCT 3′ which
hybridizes on exon 6, reverse primer 664/651 nt: 5′ GGTGCCGTGCTTGTCTCTTA 3′
located on exon 7. PCR analysis was performed using 25 ng of cDNA in a reaction
mixture containing 300 nM of forward and reverse primers and 200 nM of the
fluorescent probe, and 12.5 μl Universal master Mix. Plates were treated 2 min at 50 °C,
10 min at 95 °C and then submitted to 40 cycles of amplification at 95 °C for 15 s, 60 °C
for 1 min in the ABI Prism 7000 Sequence Detector PE Applied Biosystems (Foster City,
USA). Plasmid vector, carrying GALNS gene transcript (pCXN-GALNS), was tenfold
serially diluted from a starting quantity of 11×106 plasmid copies to 11 plasmid copies
and used as standard curve. The absolute values of GALNS gene mRNA products were
expressed as copy/μg total RNA (mean±SD).
2.7. Splice site score calculation
A numerical score expressing adherence to the consensus sequences was calculated
by the http://www.fruitfly.org/.
2.8. Statistical analysis
Statistical analysis of different real-time assay measurement was carried out using
the SPSS software package (SPSS INC, Chicago, IL). Statistical differences betweenFig. 1. A. RT-PCR analysis of MPS IVA patients. The PCR products, run on 2% agarose gel,
were obtained after total RNA retrotranscription with random hexamers and two
subsequent amplifications with the following primers:
I° PCR GALNSc1F 5′ CAGCCCAGCCGGAAGGGCC 3′
GALNSc6R 5′ GGCAAAGCTGAGGGGGAACC 3′
II° PCR (nested) GALNSc3F 5′ CAAGGCCAGGCCCAACATCC 3′
GALNSc5R 5′ ACACGTTGAGCTGGGGCTGC 3′
1. Molecular weight marker, 2. Pt 1, 3. Pt 2, 4. Normal control. B. Schematic
representation of the aberrant transcripts detected in MPS IVA Pt1. Black boxes mark
the exons, white boxes indicate exonic sequence loss.
Fig. 2. Real-time standard curve. Amplification plot showing the standard curve of
plasmid vector pCXN-GALNS, generated by seven tenfold serial dilution from a starting
quantity of 11×106 plasmid copies, and controls, Pt1 and Pt2 samples.groups were assessed by t-test. Differences with pb0.05 were considered statistically
significant.
3. Results
The fibroblasts from patients with enzymatic diagnosis of MPS IVA
disease underwent molecular characterisation (Table 1). Exons and
exon–intron boundaries of the GALNS gene were amplified and
directly sequenced on both strands.
Sequence analyses of the GALNS gene of the MPS IVA patients led
to the identification of two new alterations and a known splicing
mutation. The new c.385ANT leading to the premature stop codon p.
K129X and the c.899−1GNC splicing mutations were identified in Pt1
and the reported c.120+1GNA mutation was identified in a homo-
zygous state in Pt2.
The splice acceptor site mutation c.899−1GNC, located in intron 8,
led to the detection, by RT-PCR, of two aberrantly spliced transcripts
(Fig. 1A): transcript 1, devoid of exon 9, and transcript 2, lacking the
entire exon 9 and the first 120 bp of exon 10 (Fig. 1B). Sequence
analysis showed that both transcripts led to a frameshift, introducing a
premature stop codon.
The new c.385ANT nucleotide change, in exon 4, leading to the p.
K129X nonsense mutation, was also detected in the mRNA by
conventional RT-PCR and sequence analyses.
The known c.120+1GNA splicing mutation was identified at a
homozygous state in Pt 2 with North African background. In this
patient conventional RT-PCR analysis, performed with different
amplification primers (by both specific 3′ UTR primer and random
hexamers), on agarose gel, failed to detect, any aberrant transcript
(Fig. 1A).
Quantitative analysis of GALNS gene mRNA was performed by
absolute real-time PCR, using probe and primers encompassing exon
6–7 junction, present in all Pt1's GALNS transcripts. To determine the
quantity of mRNA in patients' specimens, pCXN-GALNS vector was
used to generate the standard curve. Results, reported in Fig. 2,
indicated that this assay effectively distinguished 10-fold differences
Table 4
Score calculation of canonical and cryptic splice sites by the http://www.fruitfly.org/
Patient Transcript Sequence Splice site
score








INT tgttgctgccatgtgtttcaggtgagccaccagctgggcag EX 0.87
Aberrant
transcript 2
INT ctcctccccaccctcctgcagggccggctgatggacaggtt EX 0.97
Pt2 Normal EX1 ggacgacgtgagtgc INT1 0.99
Mutant EX1 ggacgacatgagtgc INT1 b0.40
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reaction mixture.
We analyzed total RNA from the fibroblasts of two MPS IVA
patients and 15 normal controls. With respect to the standard
deviation, the mean value of GALNS control mRNAs was not
significantly different from that of Pt 1 sample (normal mean value:
6.76×105±3.17×105, patient's mean value 5.59×105±2.8×105 mole-
cules). Pt 2, homozygous for the c.120+1GNA mutation, showed an
almost complete absence of the GALNS mRNA (only 8.46×102±
2.61×102 molecules of GALNS mRNA were detected), confirming
conventional RT-PCR data (Fig. 2 and Table 3).
In Table 4 we report the splice site score calculated for
physiological and cryptic sites for the splicing of exon 1 and exon 9.
4. Discussion
About 150 genetic lesions have been reported in the GALNS gene of
mucopolysaccharidosis IVA (MPS IVA) patients, indicating remarkable
genetic heterogeneity.
Here we report two Mediterranean patients affected by a severe
form of the disease. We identified one known and two newmutations
causing severe genetic lesions and contributing to the wide spectrum
of allelic heterogeneity of this disease.
Computational analysis showed that these two splicing mutations
dramatically decrease the numerical score of the invariant affected
motifs (Table 4). Conventional GALNS RT-PCR analysis showed the
almost complete absence of transcripts in Pt2 while in Pt1 the
presence of three different transcripts was identified. One of such
transcripts takes advantage of a cryptic splice site inside exon 10,
whose computational score resulted to be very high (0.97).
Anyhow such end-point analysis was not precise enough to
quantify the mRNAs. We therefore developed a real-time RT-PCR
assay to quantify absolute mRNA copy numbers and to determine
whether the GALNS transcripts of Pt1 were subject to NMD
degradation.
NMD is a mechanism that, with some exceptions [16–20], down-
regulates spliced mRNAs presenting premature termination codons
about 50 to 55 nucleotides upstream of the subsequent exon–exon
junction. Consequently, it prevents the production of the potentially
toxic truncated proteins they encode [12,21].
Quantitative real-time PCR has been used in hematology and
oncology to monitor response to treatment and detect minimal
residual disease (MRD) in leukemia and lymphoma [22–24]. This
accurate quantification of mRNAs expression levels can also be utilised
for genotype–phenotype correlation and for investigating the patho-
genetic mechanism of diseases. The real-time technology is now
highly sensitive, accurate and simple enough to be adopted as a
routine method for measuring gene levels. However, although a
number of studies on real-time mRNA quantification of lysosomal
genes have been performed [25–32], only one did reported on
absolute mRNA copy number detection [33].
The presence in Pt1 of normal GALNS transcripts levels, identified
by the real-time assay technique we describe, suggests that such
mRNAs are not sensitive to NMD, according to what conventional RT-
PCR analysis has indicated.
These results increase the number of known cases in which the
nonsense-mediated mRNA decay surveillance system is bypassedTable 3
Number of GALNS copies detected in MPS IVA patients and control samples
Patient Number of copies GALNS±SD
1 5.59×105±2.8×105
2 8.46×102±2.61×102
Normal mean value 6.76×105±3.17×105[16,20,31,34,35]. Only the c.385ANT (p.K129X) mutation, which is 38
nucleotides upstream of the donor splice site of intron 4, fulfilled the
condition that PTCs located within a distance of 50 to 55 nucleotides
from the subsequent exon–exon junction do not trigger NMD. The
reason why mRNAs, such as aberrant transcripts 1 and 2, caused by Pt
1's c.899−1GNCmutation, escape mRNA surveillance is unknown, but
a modulation of NMD sensitivity mediated by additional, unidentified
factors cannot be excluded [36].
Conventional RT-PCR analysis performed on Pt 2, who carried the
c.120+1GNA at a homozygous level, failed to detect any aberrant
transcript and the more sensitive and accurate real-time RT-PCR
analysis showed very low GALNS transcript levels: only 8.46×102±
2.61×102 copies compared to the 6.76×105±3.17×105 copies of
normal controls.
In Pt2 a constitutive 5′ splice donor site is mutated with a
significant reduction of splice site score (0.99 vs b0.40). It is known
that mutations affecting constitutive 5′ splice site lead to the complete
exon skipping or to the use of a nearby cryptic site. This could lead, in
Pt2, to aberrant transcripts resulting in frame shift products contain-
ing PTCs. Such transcripts can be highly unstable and subject to NMD
[12,21]. This could explain the almost complete absence of GALNS
mRNA in this patient.
Pt 2, who was homozygous for the c.120+1GNA mutation, had
consanguineous North African parents whowere heterozygous for the
mutation. The c.120+1GNA mutation has also been described in five
Tunisian patients, with the classical form of MPS IVA, segregating in
three families [37]. These results suggest a common ancestor in North
African populations, as suggested by Laradi et al. [36].
Detection of severe mutations in these patients, leading to
truncated proteins, with potentially deleterious activities, indicates a
correlation between the genotype and severe phenotype severity.
We believe that it is important to determine the stability of PTC
bearing transcripts in MPS IVA patients in order to assess the
appropriateness of new therapeutic strategies. Recent studies indicate
that it may be possible to correct the negative effect of mutations
causing in-frame nonsense codons (stop codon read-through) using
aminoglycoside antibiotics which, by virtue of their low molecular
weight, are able to enter, by diffusion, cells, tissues and organs that are
otherwise not easily accessible [38,39]. High levels of nonsense
containing mRNAs, able to escape NMD, will result in an enhanced
level of drug-induced read-through, making transcripts, from the
allele with the c.385ANT mutation good candidates for this kind of
therapy.
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